Orphan Drug Focus Khondrion’s lead asset sonlicromanol targets primary mitochondrial diseases and has Orphan Drug Designations in the US and EU, suggesting strong potential for partnerships with specialty pharma and CROs focused on rare diseases and regulated markets.

Phase 3 Readiness As a Phase 3 ready clinical-stage company with in-house discovery and preclinical pipelines, Khondrion is positioned to leverage collaborations for late-stage development, manufacturing scale-up, and global regulatory strategy with partners that provide funding and commercialization capabilities.

Strategic Partnerships Active collaborations with patient organizations and a global clinical/academic network indicate openness to co-development, patient-centric trial designs, and data-sharing partnerships that can be attractive to potential sponsors or research partners seeking broader trial ecosystems.

Recent Financing Recent funding events including Innovation Credit support and private investment strengthen balance sheet and de-risk near-term milestones, presenting opportunities for strategic co-investments, joint development agreements, or supplier/service collaborations with financial and biopharma partners.

Funding Leverage Small to mid-size company profile with <$1M revenue and ~$9.5M funding positions Khondrion as a potential target for contract research, manufacturing, or licensing arrangements with larger biotech players seeking access to mitochondrial disease expertise and a Phase 3- ready asset pipeline.